Hemangiosarcoma is a malignant tumor and, historically, associated with a poor long term prognosis. Many beliefs about hemangiosarcoma are based on older information but recent advances in our understanding of this disease may soon change the way we approach hemangiosarcoma patients and their outcomes.

In this segment Dr. Erin Dickerson and Dr. Antonella Borgatti - two researchers at the University of Minnesota - create an understanding of the distinct subtypes of hemangiosarcoma and how these may impact survival and responses to treatment. They also update us on current accepted treatment approaches and debunk myths about others. Lastly, they will inform us about clinical trials of targeted therapies (including eBAT) and how the results are paving the way to new and improved therapies for canine hemangiosarcoma.

Running time: 59 mins
Approved for 1 hour of CE credit by AAVSB RACE and NY State